Warning: fopen(/home/virtual/enm-kes/journal/upload/ip_log/ip_log_2024-10.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 100 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 101 Metabolic Impacts of Discontinuation and Resumption of Recombinant Human Growth Hormone Treatment during the Transition Period in Patients with Childhood-Onset Growth Hormone Deficiency
Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search
Advanced Search
mobile menu button

Articles

Page Path
HOME > Endocrinol Metab > Volume 37(2); 2022 > Article
Original Article
Hypothalamus and Pituitary Gland Metabolic Impacts of Discontinuation and Resumption of Recombinant Human Growth Hormone Treatment during the Transition Period in Patients with Childhood-Onset Growth Hormone Deficiency
Keypoint
This study investigated the metabolic changes associated with interrupting growth hormone (GH) treatment in 187 adolescents with childhood-onset growth hormone deficiency (CO-GHD) during the transition period treated at six academic centers in Korea. GH interruption during the transition period resulted in deterioration of metabolic parameters, and a longer duration of interruption was associated with worse outcomes. Therefore, early recommencement of GH should be considered in CO-GHD patients during their transition period.
Yun Jeong Lee1orcid, Yunha Choi2, Han-Wook Yoo2, Young Ah Lee1, Choong Ho Shin1, Han Saem Choi3, Ho-Seong Kim3, Jae Hyun Kim4, Jung Eun Moon5, Cheol Woo Ko5, Moon Bae Ahn6, Byung-Kyu Suh6, Jin-Ho Choi2orcid
Endocrinology and Metabolism 2022;37(2):359-368.
DOI: https://doi.org/10.3803/EnM.2021.1384
Published online: April 25, 2022

1Department of Pediatrics, Seoul National University Children’s Hospital, Seoul National University College of Medicine, Seoul, Korea

2Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

3Departmend of Pediatrics, Severance Children’s Hospital, Yonsei University College of Medicine, Seoul, Korea

4Department of Pediatrics, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

5Department of Pediatrics, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea

6Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea

Corresponding author: Jin-Ho Choi. Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea Tel: +82-2-3010-3991, Fax: +82-2-473-3725, E-mail: jhc@amc.seoul.kr
• Received: December 27, 2021   • Revised: February 12, 2022   • Accepted: February 25, 2022

Copyright © 2022 Korean Endocrine Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 5,445 Views
  • 198 Download
  • 7 Web of Science
  • 10 Crossref
  • 6 Scopus
prev next
Full Article

Download PDF Download PDF

  • Background
    Discontinuing growth hormone (GH) treatment during the transition to adulthood has been associated with adverse health outcomes in patients with childhood-onset growth hormone deficiency (CO-GHD). This study investigated the metabolic changes associated with interrupting GH treatment in adolescents with CO-GHD during the transition period.
  • Methods
    This study included 187 patients with CO-GHD who were confirmed to have adult GHD and were treated at six academic centers in Korea. Data on clinical parameters, including anthropometric measurements, metabolic profiles, and bone mineral density (BMD) at the end of childhood GH treatment, were collected at the time of re-evaluation for GHD and 1 year after treatment resumption.
  • Results
    Most patients (n=182, 97.3%) had organic GHD. The median age at treatment discontinuation and re-evaluation was 15.6 and 18.7 years, respectively. The median duration of treatment interruption was 2.8 years. During treatment discontinuation, body mass index Z-scores and total cholesterol, low-density lipoprotein, and non-high-density lipoprotein (HDL) cholesterol levels increased, whereas fasting glucose levels decreased. One year after GH treatment resumption, fasting glucose levels, HDL cholesterol levels, and femoral neck BMD increased significantly. Longer GH interruption (>2 years, 60.4%) resulted in worse lipid profiles at re-evaluation. The duration of interruption was positively correlated with fasting glucose and non-HDL cholesterol levels after adjusting for covariates.
  • Conclusion
    GH treatment interruption during the transition period resulted in worse metabolic parameters, and a longer interruption period was correlated with poorer outcomes. GH treatment should be resumed early in patients with CO-GHD during the transition period.
  • Keywords: Adolescent; Body mass index; Bone density; Dyslipidemias; Growth hormone; Pituitary gland; Transition to adult care
Childhood-onset growth hormone deficiency (CO-GHD) is a pediatric-onset endocrine disorder that is associated with various health problems throughout life. Although the major role of growth hormone (GH) in children is to promote linear growth, it also exerts metabolic effects on multiple organs. These effects include enhancing anabolic protein metabolism, increasing bone mineral density (BMD), promoting lipolysis, and stimulating glucose metabolism [1,2]. Untreated patients with GHD have a high risk of developing cardiovascular disease [3,4], which is partially reversible with GH treatment [4,5].
CO-GHD is a heterogeneous disease that is divided into two types: idiopathic GHD, which may resolve by the time children reach their final height, and organic GHD, which usually requires continuous GH treatment during the transition period and even in adulthood [6]. Because somatic maturation continues even after the cessation of physical growth in patients with organic CO-GHD, optimal management during the transition to adulthood is crucial [2,7]. Discontinuation of GH treatment after reaching the final height has been associated with abnormal body composition, reduced BMD, an adverse metabolic profile with increased cardiovascular risk, and impaired quality of life [8-11].
Recent guidelines recommend that GH treatment should be continued until the final height is reached and resumed as early as possible after confirming adult GHD in patients with CO-GHD [12,13]. However, prolonged interruption of GH treatment between childhood and adulthood is frequently observed because of the high cost of treatment, lack of compliance, or recurrence of underlying diseases. Very few studies have explored metabolic derangements in patients with CO-GHD [14] and the adverse effects of prolonged treatment interruption in adolescents and young adults with CO-GHD in Korea [15].
We hypothesized that the interruption of GH treatment during the transition period would worsen the metabolic parameters in patients with CO-GHD, and that the duration of treatment discontinuation would be correlated with the magnitude of these changes. This multi-center study evaluated the clinical and endocrinological changes related to the discontinuation and resumption of GH treatment in patients with CO-GHD during the transition period. The effects of treatment interruption on metabolic parameters in adolescents and young adults with COGHD were also investigated.
Patients
Among patients diagnosed with CO-GHD (<18 years for boys and <16 years for girls at diagnosis) between 1994 and 2019 at six academic centers in Korea, 187 patients (99 boys and 88 girls) subsequently diagnosed with adult GHD and treated with recombinant human GH for >1 year were included in this study. Patients who were not diagnosed with GHD at retest and those with adult GHD who were treated for <1 year were excluded from this study (Supplemental Fig. S1).
CO-GHD was diagnosed on the basis of a peak GH level of <10 μg/L on two separate GH stimulation tests using levodopa (125 to 500 mg) and insulin tolerance tests (regular insulin 0.1 U/kg) [13]. Patients underwent re-evaluation for GHD after they had reached their final height. Adult GHD was diagnosed on the basis of a peak GH level of <5 μg/L on insulin tolerance test [12,13]. The GH level was measured using a monoclonal immunoradiometric assay (IRMA, Diagnostics Systems Laboratories Inc., Webster, TX, USA).
GH treatment during transition
During childhood, all patients received recombinant human GH, which was discontinued when they reached their final height or when their growth velocity was <2 cm/year. GH treatment was discontinued in 27 patients before they reached their final height owing to financial constraints. Adult GHD was re-evaluated at least 1 month after GH treatment discontinuation when the patients reached their final height. After re-evaluation, patients with confirmed adult GHD received GH at a dose of 0.1 to 0.4 mg/day [12]. Patients were categorized into a long-gap group (treatment discontinuation duration >2 years) and a short-gap group (treatment discontinuation duration ≤2 years).
Clinical and biochemical assessments
Data on clinical parameters, including demographics, anthropometric measurements, and laboratory findings, were retrospectively collected at the end of childhood GH treatment, at re-evaluation, and 1 year after treatment resumption. Height, weight, and body mass index (BMI) Z-scores were determined on the basis of the 2017 Korean National Growth Charts [16]. Overweight and obesity in children and adolescents were defined as BMIs above the 85th and 95th percentiles of the age-and sex-matched reference data, respectively [17]. In adults, overweight and obesity were defined as BMIs of >23 and >25 kg/m2, respectively [18]. The laboratory parameters included the levels of fasting glucose, glycated hemoglobin (HbA1c), total cholesterol, triglyceride, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, insulin-like growth factor-1 (IGF-1), and IGF-binding protein-3 (IGFBP-3). Non-HDL cholesterol levels were calculated by subtracting the HDL cholesterol level from the total cholesterol level. For patients aged <19 years, dyslipidemia was defined as the presence of any of the following: total cholesterol ≥200 mg/dL, triglycerides ≥130 mg/dL, HDL cholesterol <40 mg/dL, and LDL cholesterol ≥130 mg/dL [19]; for those aged ≥19 years old, the cutoff values were as follows: total cholesterol ≥ 240 mg/dL, triglycerides ≥200 mg/dL, HDL cholesterol <40 mg/dL, and LDL cholesterol ≥160 mg/dL [20]. BMD was measured using dual-energy X-ray absorptiometry (DXA) scan with a Lunar Prodigy DXA system (General Electric Lunar Corporation, Madison, WI, USA) or a Hologic Discovery DXA system (Hologic Inc., Waltham, MA, USA). Z-scores for the lumbar spine and femoral neck were calculated according to the Korean reference values for children and adolescents [21,22].
Statistical analysis
Statistical analyses were performed using SPSS for Windows version 25.0 (IBM Corp., Armonk, NY, USA). All continuous variables were tested for normality and presented as mean±standard deviation or medians with interquartile ranges. The Student t test or the Mann-Whitney U test was used to compare continuous variables, and the chi-square test or Fisher exact test was used to compare categorical variables between the two groups. The paired t test, Wilcoxon signed-rank test, or McNemar test was used to compare variables among the following time points: at the end of GH treatment, at GH re-evaluation, and 1 year after treatment resumption. Linear regression analysis was performed to determine the relationship between the treatment interruption period and metabolic parameters, and multivariate models were adjusted for age, sex, BMI Z-scores, and peak GH levels at re-evaluation. After excluding patients with idiopathic GHD (n=5), statistical analyses were performed to evaluate the clinical changes of patients during GH treatment interruption and the effects of this interruption period on metabolic parameters. A P value of <0.05 was considered statistically significant.
Ethical statement
This study was approved by the Institutional Review Board (IRB) of Asan Medical Center (IRB number: 2019-1598). The requirement of informed consent was exempted because of the retrospective nature of the study, and anonymized clinical data were used in this study.
Clinical characteristics of the patients
Table 1 shows the underlying etiologies of CO-GHD. Most patients (n=182, 97.3%) had organic GHD, whereas five (2.7%) had idiopathic GHD. The most common cause of GHD was craniopharyngioma (n=83, 44.4%), followed by intracranial germ cell tumor (n=49, 26.2%), and congenital hypopituitarism (n=17, 9.1%). The mean age at the time of treatment discontinuation was 15.6±2.5 years, and the mean height, weight, and BMI Z-scores were −0.92, −0.70, and −0.53, respectively (Table 2). The median duration of treatment interruption was 2.8 years (range, 0.1 to 16.2), and GH treatment was discontinued in 113 (60.4%) patients for >2 years. The mean age at re-evaluation for GHD was 18.9±2.9 years. The mean peak GH levels at reevaluation were 0.30±0.54 μg/L (range, 0.01 to 4.2), and all patients except one had peak GH levels of <3 μg/L (Fig. 1). After re-evaluation, the patients received GH at a mean dose of 0.43±0.20 mg/day (0.01 mg/kg/day) for >1 year.
GH treatment-associated changes in clinical characteristics during the transition period
After the discontinuation of GH treatment, BMI Z-scores increased from 0.40 to 0.77 (P<0.001), whereas the IGF-1 and IGFBP-3 levels decreased significantly (P<0.001 for both) (Table 2). The fasting serum glucose levels decreased from 92.2 to 87.2 mg/dL (P=0.001), whereas there was not a significant change in the HbA1c levels. Total cholesterol, LDL cholesterol, and non-HDL cholesterol levels increased during the treatment interruption period (170.6 mg/dL vs. 184.7 mg/dL, P<0.001 for total cholesterol; 103.8 mg/dL vs. 121.3 mg/dL, P=0.016 for LDL cholesterol; 131.7 mg/dL vs. 144.2 mg/dL, P=0.045 for non-HDL cholesterol) (Table 2).
After 1 year of GH treatment, the IGF-1 and IGFBP-3 levels increased significantly (P<0.001 for both). Moreover, BMI Z-scores continued to increase (P=0.002). The fasting glucose levels increased from 87.2 to 93.0 mg/dL (P=0.011), and HDL cholesterol levels increased from 43.7 to 47.2 mg/dL (P=0.032) without significant changes in other components of the lipid profile. The femoral neck BMD Z-score significantly increased from −1.10 to −0.90 after GH treatment (P=0.022). Statistical analyses excluding patients with idiopathic GHD revealed results similar to those of the analyses performed including all patients (Supplemental Table S1). The changes in clinical parameters at two time points are described in Supplemental Tables S2 (at the end of GH treatment and at the time of GH re-evaluation) and S3 (at the time of GH re-evaluation and 1 year after treatment resumption), which showed similar results as well.
Effects of the treatment discontinuation duration on clinical characteristics
When patients were compared on the basis of the duration of treatment interruption, no significant differences were noted in metabolic parameters between the long-gap (n=113) and the short-gap (n=74) groups at the end of GH treatment (Table 3). However, at re-evaluation, the long-gap group had worse lipid profiles with higher levels of total cholesterol (186.7 mg/dL vs. 175.7 mg/dL, P=0.030), triglycerides (163.9 mg/dL vs. 125.5 mg/dL, P=0.023), LDL cholesterol (120.6 mg/dL vs. 108.0 mg/dL, P=0.029), and non-HDL cholesterol (145.8 mg/dL vs. 127.1 mg/dL, P=0.002), and lower levels of HDL cholesterol (40.3 mg/dL vs. 47.1 mg/dL, P=0.004) (Table 3). After 1 year of GH treatment, the long-gap group still had higher BMI Z-scores than the short-gap group (P=0.046). Clinical characteristics before and after GH treatment were compared for each group. The results showed significant worsening of metabolic parameters in the long-gap group (Supplemental Table S4).
In univariate regression analyses, a longer duration of GH treatment interruption was significantly correlated with increases in the levels of total cholesterol (β=1.95, P=0.018), LDL cholesterol (β=3.46, P=0.005), and non-HDL cholesterol (β=4.81, P<0.001). The duration of GH treatment interruption was inversely correlated with the levels of IGF-1 (β=−4.42, P=0.007), IGFBP-3 (β=−71.21, P=0.002), and HDL cholesterol (β=−1.06, P=0.036) at re-evaluation (Table 4). After adjusting for sex, age, BMI Z-scores, and peak GH levels, the interruption period was significantly correlated with increases in the level of fasting glucose (β=0.93, P=0.019) and non-HDL cholesterol (β=3.26, P=0.046) at re-evaluation. After adjusting for covariates, no significant associations were detected between the duration of treatment interruption and clinical parameters 1 year after treatment resumption (Supplemental Table S5). Statistical analyses performed including only patients with organic GHD revealed results consistent with those of analyses performed including all patients (Supplemental Tables S6, S7).
In this multi-center study, most patients had organic GHD with low peak GH levels at re-evaluation. GH treatment was interrupted for >2 years in 60.4% of the patients. Consequently, they experienced an increase in BMI Z-scores with worsening lipid profiles after a median of 2.8 years of treatment discontinuation during the transition period; these changes did not resolve completely after 1 year of GH treatment. One year after resuming GH treatment, the HDL cholesterol levels and femoral neck BMD showed significant improvements. Patients with a longer duration of GH treatment interruption showed worse fasting glucose levels and lipid profiles at re-evaluation.
In the present study, patients’ BMI Z-scores increased, whereas their IGF-1 and IGFBP-3 levels decreased during the GH treatment interruption period; however, their BMI Z-scores did not improve even after 1 year of GH replacement therapy. Several studies have reported that GH treatment discontinuation during the transition period led to an increase in BMI [23] and fat mass, in addition to a decrease in lean body mass [11,24,25]. Although the present study could not evaluate the body composition in detail, the increased BMI Z-scores in the cohort suggest that GH treatment discontinuation influences adiposity. Several trials have reported that GH replacement therapy during the transition period had a beneficial effect on body composition [8-11]; however, another study reported no changes in body composition after 2 years of treatment interruption [26]. A retrospective cohort study, similar to the present study, demonstrated a continual increase in BMI regardless of GH treatment during the transition period [27]. In the present study, the lack of improvement in BMI after resuming GH treatment might be attributed to the short treatment duration that was insufficient to overcome the effects of prolonged treatment interruption.
Worsening of the lipid profile, with increased levels of total cholesterol, LDL cholesterol, and non-HDL cholesterol during GH cessation, was noted in this study; however, improvements in the levels of HDL cholesterol were observed after 1 year of GH replacement therapy. GH induces lipolysis in adipocytes and plays an important role in the regulation of lipoprotein metabolism [1]; therefore, adult GHD may result in dyslipidemia and abdominal fat deposition. As observed in the present study, other studies have noted that patients with CO-GHD often experience unfavorable changes in their lipid profiles, with increased LDL cholesterol and triglyceride levels after discontinuing GH treatment when they reach their final height [28-30]. GH replacement therapy during the transition period has been associated with decreased levels of total and LDL cholesterol in some studies [10,15,27], but not all [8,26,31]. This might be related to different durations of follow-up or the heterogeneous nature of CO-GHD.
GH may enhance insulin sensitivity by improving body composition; however, it also stimulates glycogenolysis, gluconeogenesis, and lipolysis, thereby increasing blood glucose levels and inducing insulin resistance in the short term [32]. The patients in the present study had decreased fasting blood glucose levels after treatment discontinuation, which increased after treatment resumption. This is consistent with the findings of other studies [8,11,30]. Mild insulin resistance has been noted after short-term GH substitution in children and adults with GHD; however, the serum glucose levels remained within the normal range in most studies [5,33]. Long-term low-dose GH treatment may improve glucose metabolism in adult patients with GHD [3].
Although BMD was evaluated in only a small number of patients in the present study, a significant improvement was observed in femoral neck BMD after GH treatment resumption. Several studies have reported the positive effects of GH replacement therapy on bone mass when patients with CO-GHD reached their final height [10,34,35]. Increased BMD was particularly apparent in the lumbar spine [10,34,35] but was also observed in the femoral neck [34,35]. However, the lack of changes in spine BMD and the lack of a control group in the present study made it difficult to confirm whether the observed improvement in femoral neck BMD was due to GH replacement therapy. Young adults with CO-GHD have been reported to show an initial temporary loss of BMD for several months after treatment resumption, followed by a subsequent increase in BMD [10,34]. This observation can be explained by a biphasic model of GH action, with an initial predominant bone resorption phase followed by increased bone formation [2]. Consequently, the net gain of bone mass usually takes >1 year, indicating the need for long-term follow-up to determine the real effects of GH treatment on BMD during the transition period. Attaining peak bone mass during the transition period is a crucial determinant of lifelong bone health [36], and further studies focusing on the long-term effects of GH treatment during the transition period are warranted.
In the present study, patients with a longer duration of GH treatment interruption had worse metabolic profiles and lower levels of IGF-1 at re-evaluation. After adjustment for covariates, the duration of treatment interruption was noted to be significantly associated with increases in the levels of fasting blood glucose and non-HDL cholesterol. This suggests that long-term discontinuation of GH treatment results in compromised body composition and, consequently, worsens glucose and lipid metabolism. Longer GH treatment interruption has also been associated with a worse lipid profile or lower BMD in previous studies [29,37]. Although one clinical trial reported that at least 2 years of GH cessation was safe in adolescents with good metabolic status [26], the optimal shortest period of treatment discontinuation before re-evaluation has not been clarified [38].
Current guidelines recommend re-evaluating patients for GHD at least 1 month after the discontinuation of pediatric GH treatment, particularly in patients with idiopathic isolated GHD. However, in patients with organic causes such as genetic or structural defects in the hypothalamic–pituitary region, re-evaluation is not required, and GH replacement therapy can be continued without interruption [12]. Although most patients in the present study had organic causes of GHD, the duration of GH treatment interruption was long (median, 2.8 years) because of the early discontinuation of GH treatment owing to the cost of treatment or lack of insurance coverage during the transition period. All patients except one showed peak GH levels of <3 μg/L in this study, which also supports the current recommendation that re-evaluation is not required in patients with organic causes of GHD [12]. The recent guidelines of the Korean Endocrine Society and Korean Society of Pediatric Endocrinology also recommend that GH replacement should be continued in patients with CO-GHD until they reach their final height and should be resumed as early as possible during the transition [13].
This study has some limitations. First, the retrospective design of the study resulted in missing data on some clinical parameters such as fasting glucose and insulin levels, lipid profiles, family history, nutritional status, physical activity, adherence to GH treatment, and quality of life. Furthermore, this study evaluated neither the proportion of patients with adult GHD among those with CO-GHD nor the influence of other anterior pituitary hormone deficiencies. However, most patients had organic lesions with multiple pituitary hormone deficiencies, and the sensitivity analysis showed results consistent with those of the analysis including all patients. Second, this study did not include any control group without GH treatment. Finally, the duration of GH treatment after re-evaluation was short, and the long-term consequences of GH replacement therapy could not be evaluated. Thus, the effect of GH treatment on metabolic profiles might have been misinterpreted. Nevertheless, this is the first multi-center study to demonstrate the current treatment status and importance of GH treatment in patients with CO-GHD during the transition period in Korea. Because most of these patients were confirmed to have organic GHD, the study focused on the effects of GH treatment interruption in a relatively homogeneous group of patients.
In conclusion, adolescents and young adults with CO-GHD exhibited worsened metabolic profiles after GH treatment interruption during the transition period, and these unfavorable changes were not fully reversible after 1 year of GH treatment. A longer duration of treatment discontinuation was associated with worse outcomes, and studies aiming at shortening this duration are warranted in the future.
Supplemental Table S1.
Changes in Clinical Characteristics at the End of GH Treatment, at Re-Evaluation, and 1 Year after Treatment Resumption in Patients with Organic Growth Hormone Deficiency and Complete Data at All Visits
enm-2021-1384-suppl1.pdf
Supplemental Table S2.
Changes in Clinical Characteristics between at the End of GH Treatment and at Re-Evaluation
enm-2021-1384-suppl2.pdf
Supplemental Table S3.
Changes in Clinical Characteristics between at Re-Evaluation and 1 Year after Treatment Resumption
enm-2021-1384-suppl3.pdf
Supplemental Table S4.
Comparison of Clinical Characteristics at Re-Evaluation and 1 Year after Treatment Resumption in Long-Gap and Short-Gap Group
enm-2021-1384-suppl4.pdf
Supplemental Table S5.
Association of Clinical Characteristics with Duration of GH Treatment Interruption (Years) after 1 Year of Treatment Resumption
enm-2021-1384-suppl5.pdf
Supplemental Table S6.
Comparison of Clinical Characteristics by the Duration of GH Treatment Interruption in Patients with Organic Growth Hormone Deficiency
enm-2021-1384-suppl6.pdf
Supplemental Table S7.
Association of Clinical Characteristics with Duration of GH treatment Interruption (Years) at Re-Evaluation in Patients with Organic Growth Hormone Deficiency
enm-2021-1384-suppl7.pdf
Supplemental Fig. S1.
A flowchart illustrating the inclusion and exclusion criteria in this study. Among patients diagnosed with childhoodonset growth hormone deficiency (CO-GHD) between 1994 and 2019 in six academic centers in Korea, 187 patients (99 boys and 88 girls) subsequently diagnosed with adult GHD and treated with recombinant human growth hormone (GH) for >1 year were included. The patients who were not diagnosed with GHD at retest and those with adult GHD who were treated for <1 year were excluded from this study.
enm-2021-1384-suppl8.pdf

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

AUTHOR CONTRIBUTIONS

Conception or design: C.H.S., J.H.C. Acquisition, analysis, or interpretation of data: Y.J.L., Y.C., H.W.Y., Y.A.L., C.H.S., H. S.C., H.S.K., J.H.K., J.E.M., C.W.K., M.B.A., B.K.S., J.H.C. Drafting the work or revising: Y.J.L., Y.C., J.H.C. Final approval of the manuscript: Y.J.L., Y.C., H.W.Y., Y.A.L., C.H.S., H.S.C., H.S.K., J.H.K., J.E.M., C.W.K., M.B.A., B.K.S., J.H.C.

Acknowledgements
This work was supported by a grant (2019-04) from the Korean Society of Pediatric Endocrinology
Fig. 1.
Peak growth hormone (GH) levels on GH stimulation tests at re-evaluation according to the underlying etiologies of childhood-onset growth hormone deficiency (CO-GHD).
enm-2021-1384f1.jpg
Table 1.
Etiology of Childhood-Onset Growth Hormone Deficiency
Etiology No. of patients (%)
Neoplastic
  Craniopharyngioma 83 (44.4)
Intracranial germ cell tumor 49 (26.2)
Pituitary adenoma 6 (3.2)
Optic glioma, suprasellar astrocytoma 4 (2.1)
Rathke’s cleft cyst 4 (2.1)
Congenital
Congenital hypopituitarism 17 (9.1)
Congenital structural anomaly (hydrocephalus or syringomyelia) 4 (2.1)
Infiltrative
Hypophysitis 3 (1.6)
Langerhans cell histiocytosis 2 (1.1)
Cranial irradiation
Cranial tumors distant from pituitary/hypothalamus area 9 (4.8)
Acute lymphoblastic leukemia 1 (0.5)
Idiopathic growth hormone deficiency 5 (2.7)
Table 2.
Changes in Clinical Characteristics at the End of GH Treatment, at the Time of Re-Evaluation, and 1 Year after Treatment Resumption in Patients with Complete Data at All Visits
Characteristic No. At the end of GH treatment At the time of re-evaluation One year after GH treatment resumption P (end of GH treatment vs. at re-evaluation) P (at re-evaluation vs. after 1 year)
Age, yr 187 15.6±2.5 18.9±2.9 20.0±3.0 - -
Height, cm 183 158.3±11.6 163.9±9.1 165.3±9.3 <0.001 <0.001
Weight, kg 179 56.4±14.1 65.0±15.2 67.6±15.5 <0.001 <0.001
Body mass index, kg/m2 179 22.4±4.1 24.2±4.8 24.7±4.8 <0.001 <0.001
Height Z-score 183 −0.92±1.30 −0.70±1.48 −0.53±1.50 <0.001 <0.001
Weight Z-score 179 −0.14±1.44 0.31±1.67 0.55±1.64 <0.001 <0.001
Body mass index Z-score 179 0.40±1.42 0.77±1.66 0.93±1.66 <0.001 0.002
Overweight and/or obesity 179 59 (33.0) 86 (48.0) 103 (57.5) <0.001 0.002
IGF-1, μg/L 150 316.3±228.9 81.1±70.0 164.0±114.7 <0.001 <0.001
IGFBP-3, μg/L 74 3,247.9±1,521.9 1,772.6±612.0 2,261.4±798.8 <0.001 < 0.001
Fasting plasma glucose, mg/dL 114 92.2±11.7 87.2±11.8 93.0±22.1 0.001 0.011
Glycated hemoglobin, % 64 5.5±0.8 5.4±0.4 5.5±1.0 0.141 0.332
Prediabetes/diabetes 57 31 (54.4) 23 (40.4) 30 (52.6) 0.096 0.118
Total cholesterol, mg/dL 130 170.6±34.1 184.7±33.6 184.3±38.9 <0.001 0.858
Triglycerides, mg/dL 66 141.8±71.2 149 9±75.4 159.6±90.0 0.412 0.510
HDL cholesterol, mg/dL 30 48.8±12.3 43.7±11.9 47.2±12.9 0.076 0.032
LDL cholesterol, mg/dL 30 103.8±30.9 121.3±40.1 113.9±34.6 0.016 0.240
Non-HDL cholesterol, mg/dL 30 131.7±26.1 144.2±38.7 139.9±38.7 0.045 0.520
Dyslipidemia 40 33 (82.5) 32 (80.0) 28 (70.0) 0.999 0.125
Lumbar spine BMD Z-score 27 - −1.50 (−2.40 to −0.65) −1.60 (−2.40 to −0.90) - 0.188
Femoral neck BMD Z-score 21 - −1.10 (−1.90 to −0.25) −0.90 (−1.60 to −0.05) - 0.022

Values are expressed as mean±standard deviation, number (%), or median (interquartile range).

GH, growth hormone; IGF-1, insulin-like growth factor-1; IGFBP-3, IGF-binding protein-3; HDL, high-density lipoprotein; LDL, low-density lipoprotein; BMD, bone mineral density.

Table 3.
Comparison of Clinical Characteristics by the Length of GH Treatment Interruption
Variable At the end of GH treatment
Treatment interruption >2 years
 Treatment interruption ≤2 years
 Treatment interruption >2 years
 Treatment interruption ≤2 years
 Treatment interruption >2 years
 Treatment interruption ≤2 years
No. Value No. Value No. Value No. Value No. Value No. Value
Body mass index, kg/m2 112 22.2±3.9 73 22.4±4.6 113 24.6±4.9a 74 23.1±4.6a 110 25.2±4.7 71 23.8±4.8
Body mass index Z-score 112 0.5±1.3 73 0.2±1.6 113 0.91±1.71 74 0.44±1.58 110 1.12±1.65a 71 0.62±1.62a
IGF-1, μg/L 91 317.6±246.7 64 311.1±198.1 113 69.3±49.8a 74 94.6±85.5a 112 163.5±102.4 69 172.8±136.8
IGFBP-3, μg/L 3,294.0±1,566.4a 25 2,475.2±1,095.5a 85 1,788.4±672.9 18 2,152.5±943.5 85 2,272.5±863.3 32 2,396.0±905.9
Fasting glucose, mg/dL 85 93.0±12.4 44 90.4±11.7 109 87.8±13.2 70 87.3 ±10.4 97 94.7±27.5 52 91.9±13.4
Glycated hemoglobin, % 68 5.4±0.4 56 5.4±0.9 78 5.5±0.5 36 5.3±0.5 82 5.5±0.8 59 5.4±0.9
Total cholesterol, mg/dL 92 171.4±30.3 48 167.7±40.7 111 186.7±35.5a 70 175.7±29.0a 108 188.6±41.8 61 176.6±34.9
Triglycerides, mg/dL 63 146.9±77.9 20 125.0±66.8 101 163.9±137.0a 62 125.5±76.7a 88 165.3±93.8 40 138.4±70.8
HDL cholesterol, mg/dL 29 46.9±12.0 13 48.0±13.0 58 40.3±11.9b 54 47.1±12.6b 48 48.8±15.2 33 48.0±11.8
LDL cholesterol, mg/dL 29 102.5±27.6 13 103.8±30.9 58 120.6±35.2a 54 108.0±24.2a 48 112.5±34.8 33 110.5±26.7
Non-HDL cholesterol, mg/dL 29 133.3±25.9 13 123.8±25.8 58 145.8±33.1b 54 127.1±27.7b 48 137.7±37.4 33 131.8±24.8
Lumbar spine BMD Z-score - - - - 54 −1.4 (−2.4 to −0.8) 6 −1.7 (−2.7 to −0.2) 31 −1.6 (−2.4 to −0.7) 8 −1.7 (−2.8 to −1.6)
Femoral neck BMD Z-score - - - - 43 −1.0 (−1.8 to −0.3) 6 −1.6 (−2.1 to 0.2) 29 −0.9 (−1.2 to −0.1) 8 −0.9 (−1.7 to 0.2)

Values are expressed as mean±standard deviation or median (interquartile range).

GH, growth hormone; IGF-1, insulin-like growth factor-1; IGFBP-3, IGF-binding protein-3; HDL, high-density lipoprotein; LDL, low-density lipoprotein; BMD, bone mineral density.

a P<0.05;

b P<0.01.

Table 4.
Associations of Clinical Characteristics with the Duration of GH Treatment Interruption (years) at Re-Evaluation
Outcome variable Unadjusted, β (95% CI) Adjusted, β (95% CI)c
Body mass index, kg/m2 0.12 (−0.11 to 0.35) −0.03 (−0.33 to 0.27)
Body mass index Z-score 0.04 (−0.04 to 0.12) −0.01 (−0.10 to 0.08)
IGF-1, μg/L −4.42 (−7.60 to −1.25)b −2.19 (−5.95 to 1.57)
IGFBP-3, μg/L −71.21 (−114.18 to −28.23)b −52.00 (−105.16 to 1.16)
Fasting glucose, mg/dL 0.53 (−0.06 to 1.12) 0.93 (0.16 to 1.70)a
Glycated hemoglobin, % 0.01 (−0.02 to 0.04) 0.00 (−0.04 to 0.04)
Total cholesterol, mg/dL 1.95 (0.35 to 3.55)a 1.44 (-0.69 to 3.57)
Triglycerides, mg/dL 4.80 (−1.09 to 10.69) 4.13 (−3.84 to 12.09)
HDL cholesterol, mg/dL −1.06 (−2.03 to −0.08)a −0.79 (−2.10 to 0.51)
LDL cholesterol, mg/dL 3.46 (1.11 to 5.81)b 2.00 (−1.14 to 5.14)
Non-HDL cholesterol, mg/dL 4.81 (2.46 to 7.16)b 3.26 (0.10 to 6.42)a

GH, growth hormone; CI, confidence interval; IGF-1, insulin-like growth factor-1; IGFBP-3, IGF-binding protein-3; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

a P<0.05;

b P<0.01;

c Models were adjusted for age, sex, peak growth hormone levels at re-evaluation for body mass index and body mass index Z-scores; the models were adjusted for age, sex, body mass index Z-scores, and peak GH levels for other parameters.

  • 1. Rothermel J, Reinehr T. Metabolic alterations in paediatric GH deficiency. Best Pract Res Clin Endocrinol Metab 2016;30:757–70.ArticlePubMed
  • 2. Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg MC. Growth hormone and bone. Endocr Rev 1998;19:55–79.ArticlePubMed
  • 3. Gazzaruso C, Gola M, Karamouzis I, Giubbini R, Giustina A. Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH: an update. J Clin Endocrinol Metab 2014;99:18–29.ArticlePubMed
  • 4. Capalbo D, Mattace Raso G, Esposito A, Di Mase R, Barbieri F, Meli R, et al. Cluster of cardiometabolic risk factors in children with GH deficiency: a prospective, case-control study. Clin Endocrinol (Oxf) 2014;80:856–62.ArticlePubMed
  • 5. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P, et al. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab 2004;89:2192–9.ArticlePubMed
  • 6. Yuen K, Alter CA, Miller BS, Gannon AW, Tritos NA, Samson SL, et al. Adult growth hormone deficiency: optimizing transition of care from pediatric to adult services. Growth Horm IGF Res 2021;56:101375.ArticlePubMed
  • 7. Sbardella E, Pozza C, Isidori AM, Grossman AB. Endocrinology and adolescence: dealing with transition in young patients with pituitary disorders. Eur J Endocrinol 2019;181:R155–71.ArticlePubMed
  • 8. Carroll PV, Drake WM, Maher KT, Metcalfe K, Shaw NJ, Dunger DB, et al. Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth. J Clin Endocrinol Metab 2004;89:3890–5.ArticlePubMed
  • 9. Attanasio AF, Shavrikova E, Blum WF, Cromer M, Child CJ, Paskova M, et al. Continued growth hormone (GH) treatment after final height is necessary to complete somatic development in childhood-onset GH-deficient patients. J Clin Endocrinol Metab 2004;89:4857–62.ArticlePubMed
  • 10. Underwood LE, Attie KM, Baptista J; Genentech Collaborative Study Group. Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: a twoyear, multicenter, multiple-dose, placebo-controlled study. J Clin Endocrinol Metab 2003;88:5273–80.ArticlePubMed
  • 11. Vahl N, Juul A, Jorgensen JO, Orskov H, Skakkebaek NE, Christiansen JS. Continuation of growth hormone (GH) replacement in GH-deficient patients during transition from childhood to adulthood: a two-year placebo-controlled study. J Clin Endocrinol Metab 2000;85:1874–81.ArticlePubMed
  • 12. Yuen K, Biller B, Radovick S, Carmichael JD, Jasim S, Pantalone KM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. Endocr Pract 2019;25:1191–232.ArticlePubMed
  • 13. Kim JH, Chae HW, Chin SO, Ku CR, Park KH, Lim DJ, et al. Diagnosis and treatment of growth hormone deficiency: a position statement from Korean Endocrine Society and Korean Society of Pediatric Endocrinology. Endocrinol Metab (Seoul) 2020;35:272–87.ArticlePubMedPMC
  • 14. Lim HH, Kang MJ, Yun IS, Lee YA, Shin CH, Yang SW. Prevalence and risk factors of the metabolic syndrome in young adults with childhood-onset hypopituitary growth hormone deficiency. Korean J Pediatr 2010;53:892–7.ArticlePubMedPMC
  • 15. Kim JH, Cho JH, Yoo HW, Choi JH. Efficacy of growth hormone therapy in adults with childhood-onset growth hormone deficiency. Ann Pediatr Endocrinol Metab 2014;19:32–5.ArticlePubMedPMC
  • 16. Kim JH, Yun S, Hwang SS, Shim JO, Chae HW, Lee YJ, et al. The 2017 Korean National Growth Charts for children and adolescents: development, improvement, and prospects. Korean J Pediatr 2018;61:135–49.ArticlePubMedPMC
  • 17. Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, et al. Pediatric obesity-assessment, treatment, and prevention: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2017;102:709–57.ArticlePubMedPMC
  • 18. Kim BY, Kang SM, Kang JH, Kang SY, Kim KK, Kim KB, et al. 2020 Korean Society for the Study of Obesity guidelines for the management of obesity in Korea. J Obes Metab Syndr 2021;30:81–92.ArticlePubMedPMC
  • 19. Lim JS, Kim EY, Kim JH, Yoo JH, Yi KH, Chae HW, et al. 2017 Clinical practice guidelines for dyslipidemia of Korean children and adolescents. Ann Pediatr Endocrinol Metab 2020;25:199–207.ArticlePubMedPMC
  • 20. Rhee EJ, Kim HC, Kim JH, Lee EY, Kim BJ, Kim EM, et al. 2018 Guidelines for the management of dyslipidemia. Korean J Intern Med 2019;34:723–71.ArticlePubMedPMC
  • 21. Lim JS, Hwang JS, Lee JA, Kim DH, Park KD, Cheon GJ, et al. Bone mineral density according to age, bone age, and pubertal stages in Korean children and adolescents. J Clin Densitom 2010;13:68–76.ArticlePubMed
  • 22. Kang MJ, Hong HS, Chung SJ, Lee YA, Shin CH, Yang SW. Body composition and bone density reference data for Korean children, adolescents, and young adults according to age and sex: results of the 2009-2010 Korean National Health and Nutrition Examination Survey (KNHANES). J Bone Miner Metab 2016;34:429–39.ArticlePubMed
  • 23. Bazarra-Castro MA, Sievers C, Schwarz HP, Pozza SB, Stalla GK. Changes in BMI and management of patients with childhood onset growth hormone deficiency in the transition phase. Exp Clin Endocrinol Diabetes 2012;120:507–10.ArticlePubMed
  • 24. Binder G, Donner J, Becker B, Bauer JL, Schweizer R. Changes in body composition in male adolescents with childhood-onset GH deficiency during transition. Clin Endocrinol (Oxf) 2019;91:432–9.ArticlePubMed
  • 25. Boot AM, van der Sluis IM, Krenning EP, de Muinck Keizer-Schrama SM. Bone mineral density and body composition in adolescents with childhood-onset growth hormone deficiency. Horm Res 2009;71:364–71.ArticlePubMed
  • 26. Mauras N, Pescovitz OH, Allada V, Messig M, Wajnrajch MP, Lippe B, et al. Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial. J Clin Endocrinol Metab 2005;90:3946–55.ArticlePubMed
  • 27. Courtillot C, Baudoin R, Du Souich T, Saatdjian L, Tejedor I, Pinto G, et al. Monocentric study of 112 consecutive patients with childhood onset GH deficiency around and after transition. Eur J Endocrinol 2013;169:587–96.ArticlePubMed
  • 28. Rothermel J, Lass N, Bosse C, Reinehr T. Impact of discontinuation of growth hormone treatment on lipids and weight status in adolescents. J Pediatr Endocrinol Metab 2017;30:749–57.ArticlePubMed
  • 29. Koltowska-Haggstrom M, Geffner ME, Jonsson P, Monson JP, Abs R, Hana V, et al. Discontinuation of growth hormone (GH) treatment during the transition phase is an important factor determining the phenotype of young adults with nonidiopathic childhood-onset GH deficiency. J Clin Endocrinol Metab 2010;95:2646–54.ArticlePubMed
  • 30. Colao A, Di Somma C, Salerno M, Spinelli L, Orio F, Lombardi G. The cardiovascular risk of GH-deficient adolescents. J Clin Endocrinol Metab 2002;87:3650–5.ArticlePubMed
  • 31. Camtosun E, Siklar Z, Berberoglu M. Prospective follow-up of children with idiopathic growth hormone deficiency after termination of growth hormone treatment: is there really need for treatment at transition to adulthood? J Clin Res Pediatr Endocrinol 2018;10:247–55.ArticlePubMedPMC
  • 32. Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 2009;30:152–77.ArticlePubMed
  • 33. Ciresi A, Giordano C. Glucose metabolism in children with growth hormone deficiency. Front Endocrinol (Lausanne) 2018;9:321.ArticlePubMedPMC
  • 34. Conway GS, Szarras-Czapnik M, Racz K, Keller A, Chanson P, Tauber M, et al. Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency. Eur J Endocrinol 2009;160:899–907.ArticlePubMed
  • 35. Shalet SM, Shavrikova E, Cromer M, Child CJ, Keller E, Zapletalova J, et al. Effect of growth hormone (GH) treatment on bone in postpubertal GH-deficient patients: a 2-year randomized, controlled, dose-ranging study. J Clin Endocrinol Metab 2003;88:4124–9.ArticlePubMed
  • 36. Kralick AE, Zemel BS. Evolutionary perspectives on the developing skeleton and implications for lifelong health. Front Endocrinol (Lausanne) 2020;11:99.ArticlePubMedPMC
  • 37. Tritos NA, Hamrahian AH, King D, Greenspan SL, Cook DM, Jonsson PJ, et al. A longer interval without GH replacement and female gender are associated with lower bone mineral density in adults with childhood-onset GH deficiency: a KIMS database analysis. Eur J Endocrinol 2012;167:343–51.ArticlePubMedPMC
  • 38. Ahmid M, Ahmed SF, Shaikh MG. Childhood-onset growth hormone deficiency and the transition to adulthood: current perspective. Ther Clin Risk Manag 2018;14:2283–91.ArticlePubMedPMC

Figure & Data

References

    Citations

    Citations to this article as recorded by  
    • Ghrelin regulating liver activity and its potential effects on liver fibrosis and Echinococcosis
      Jiang Zhu, Tanfang Zhou, Meng Menggen, Kalibixiati Aimulajiang, Hao Wen
      Frontiers in Cellular and Infection Microbiology.2024;[Epub]     CrossRef
    • Composición de la microbiota en pacientes con déficit de hormona de crecimiento antes y después de recibir tratamiento
      Patricia García Navas, María Yolanda Ruíz del Prado, Pablo Villoslada Blanco, Emma Recio Fernández, María Ruíz del Campo, Patricia Pérez Matute
      Anales de Pediatría.2024; 100(6): 404.     CrossRef
    • Composition of the microbiota in patients with growth hormone deficiency before and after treatment with growth hormone
      Patricia García Navas, María Yolanda Ruíz del Prado, Pablo Villoslada Blanco, Emma Recio Fernández, María Ruíz del Campo, Patricia Pérez Matute
      Anales de Pediatría (English Edition).2024; 100(6): 404.     CrossRef
    • Clinical Management of Postoperative Growth Hormone Deficiency in Hypothalamic-Pituitary Tumors
      Pedro Iglesias
      Journal of Clinical Medicine.2024; 13(15): 4307.     CrossRef
    • An Overview of Cardiovascular Risk in Pituitary Disorders
      Georgia Ntali, Vyron Markussis, Alexandra Chrisoulidou
      Medicina.2024; 60(8): 1241.     CrossRef
    • The role of IGF1 in determining body composition in children and adolescents with growth hormone deficiency and those with idiopathic short stature
      Hussein Zaitoon, Michal Yackobovitch-Gavan, Eyas Midlej, Adi Uretzky, Irina Laurian, Anna Dorfman, Hagar Interator, Yael Lebenthal, Avivit Brener
      Endocrine.2024;[Epub]     CrossRef
    • Policy for transitioning childhood-onset growth hormone deficiency from pediatric to adult endocrine care in Belgium
      Willem Staels, Jean De Schepper, Marianne Becker, Philippe Lysy, Daniel Klink, Karl Logghe, Marieken den Brinker, Anne Rochtus, Bruno Lapauw, Martine Cools, Orsalia Alexopoulou, Marie Bex, Bernard Corvilain, Laurent Crenier, Christophe De Block, Julian Do
      Frontiers in Endocrinology.2024;[Epub]     CrossRef
    • Transition Period and Young Adulthood in Patients with Childhood Onset Growth Hormone Deficiency (COGHD): Impact of Growth Hormone Replacement on Bone Mass and Body Composition
      Mirjana Doknic, Marko Stojanovic, Aleksandra Markovic
      International Journal of Molecular Sciences.2024; 25(19): 10313.     CrossRef
    • Relationship between the Stimulated Peak Growth Hormone Level and Metabolic Parameters in Children with Growth Hormone Deficiency
      Seong Yong Lee
      The Ewha Medical Journal.2023;[Epub]     CrossRef
    • Dyslipidaemia and growth hormone deficiency – A comprehensive review
      Matthias Hepprich, Fahim Ebrahimi, Emanuel Christ
      Best Practice & Research Clinical Endocrinology & Metabolism.2023; 37(6): 101821.     CrossRef

    Figure
    • 0
    Metabolic Impacts of Discontinuation and Resumption of Recombinant Human Growth Hormone Treatment during the Transition Period in Patients with Childhood-Onset Growth Hormone Deficiency
    Image
    Fig. 1. Peak growth hormone (GH) levels on GH stimulation tests at re-evaluation according to the underlying etiologies of childhood-onset growth hormone deficiency (CO-GHD).

    Fig. 1.

    Metabolic Impacts of Discontinuation and Resumption of Recombinant Human Growth Hormone Treatment during the Transition Period in Patients with Childhood-Onset Growth Hormone Deficiency
    Etiology No. of patients (%)
    Neoplastic
      Craniopharyngioma 83 (44.4)
    Intracranial germ cell tumor 49 (26.2)
    Pituitary adenoma 6 (3.2)
    Optic glioma, suprasellar astrocytoma 4 (2.1)
    Rathke’s cleft cyst 4 (2.1)
    Congenital
    Congenital hypopituitarism 17 (9.1)
    Congenital structural anomaly (hydrocephalus or syringomyelia) 4 (2.1)
    Infiltrative
    Hypophysitis 3 (1.6)
    Langerhans cell histiocytosis 2 (1.1)
    Cranial irradiation
    Cranial tumors distant from pituitary/hypothalamus area 9 (4.8)
    Acute lymphoblastic leukemia 1 (0.5)
    Idiopathic growth hormone deficiency 5 (2.7)
    Characteristic No. At the end of GH treatment At the time of re-evaluation One year after GH treatment resumption P (end of GH treatment vs. at re-evaluation) P (at re-evaluation vs. after 1 year)
    Age, yr 187 15.6±2.5 18.9±2.9 20.0±3.0 - -
    Height, cm 183 158.3±11.6 163.9±9.1 165.3±9.3 <0.001 <0.001
    Weight, kg 179 56.4±14.1 65.0±15.2 67.6±15.5 <0.001 <0.001
    Body mass index, kg/m2 179 22.4±4.1 24.2±4.8 24.7±4.8 <0.001 <0.001
    Height Z-score 183 −0.92±1.30 −0.70±1.48 −0.53±1.50 <0.001 <0.001
    Weight Z-score 179 −0.14±1.44 0.31±1.67 0.55±1.64 <0.001 <0.001
    Body mass index Z-score 179 0.40±1.42 0.77±1.66 0.93±1.66 <0.001 0.002
    Overweight and/or obesity 179 59 (33.0) 86 (48.0) 103 (57.5) <0.001 0.002
    IGF-1, μg/L 150 316.3±228.9 81.1±70.0 164.0±114.7 <0.001 <0.001
    IGFBP-3, μg/L 74 3,247.9±1,521.9 1,772.6±612.0 2,261.4±798.8 <0.001 < 0.001
    Fasting plasma glucose, mg/dL 114 92.2±11.7 87.2±11.8 93.0±22.1 0.001 0.011
    Glycated hemoglobin, % 64 5.5±0.8 5.4±0.4 5.5±1.0 0.141 0.332
    Prediabetes/diabetes 57 31 (54.4) 23 (40.4) 30 (52.6) 0.096 0.118
    Total cholesterol, mg/dL 130 170.6±34.1 184.7±33.6 184.3±38.9 <0.001 0.858
    Triglycerides, mg/dL 66 141.8±71.2 149 9±75.4 159.6±90.0 0.412 0.510
    HDL cholesterol, mg/dL 30 48.8±12.3 43.7±11.9 47.2±12.9 0.076 0.032
    LDL cholesterol, mg/dL 30 103.8±30.9 121.3±40.1 113.9±34.6 0.016 0.240
    Non-HDL cholesterol, mg/dL 30 131.7±26.1 144.2±38.7 139.9±38.7 0.045 0.520
    Dyslipidemia 40 33 (82.5) 32 (80.0) 28 (70.0) 0.999 0.125
    Lumbar spine BMD Z-score 27 - −1.50 (−2.40 to −0.65) −1.60 (−2.40 to −0.90) - 0.188
    Femoral neck BMD Z-score 21 - −1.10 (−1.90 to −0.25) −0.90 (−1.60 to −0.05) - 0.022
    Variable At the end of GH treatment
    Treatment interruption >2 years
    		 Treatment interruption ≤2 years
    		 Treatment interruption >2 years
    		 Treatment interruption ≤2 years
    		 Treatment interruption >2 years
    		 Treatment interruption ≤2 years
    No. Value No. Value No. Value No. Value No. Value No. Value
    Body mass index, kg/m2 112 22.2±3.9 73 22.4±4.6 113 24.6±4.9a 74 23.1±4.6a 110 25.2±4.7 71 23.8±4.8
    Body mass index Z-score 112 0.5±1.3 73 0.2±1.6 113 0.91±1.71 74 0.44±1.58 110 1.12±1.65a 71 0.62±1.62a
    IGF-1, μg/L 91 317.6±246.7 64 311.1±198.1 113 69.3±49.8a 74 94.6±85.5a 112 163.5±102.4 69 172.8±136.8
    IGFBP-3, μg/L 3,294.0±1,566.4a 25 2,475.2±1,095.5a 85 1,788.4±672.9 18 2,152.5±943.5 85 2,272.5±863.3 32 2,396.0±905.9
    Fasting glucose, mg/dL 85 93.0±12.4 44 90.4±11.7 109 87.8±13.2 70 87.3 ±10.4 97 94.7±27.5 52 91.9±13.4
    Glycated hemoglobin, % 68 5.4±0.4 56 5.4±0.9 78 5.5±0.5 36 5.3±0.5 82 5.5±0.8 59 5.4±0.9
    Total cholesterol, mg/dL 92 171.4±30.3 48 167.7±40.7 111 186.7±35.5a 70 175.7±29.0a 108 188.6±41.8 61 176.6±34.9
    Triglycerides, mg/dL 63 146.9±77.9 20 125.0±66.8 101 163.9±137.0a 62 125.5±76.7a 88 165.3±93.8 40 138.4±70.8
    HDL cholesterol, mg/dL 29 46.9±12.0 13 48.0±13.0 58 40.3±11.9b 54 47.1±12.6b 48 48.8±15.2 33 48.0±11.8
    LDL cholesterol, mg/dL 29 102.5±27.6 13 103.8±30.9 58 120.6±35.2a 54 108.0±24.2a 48 112.5±34.8 33 110.5±26.7
    Non-HDL cholesterol, mg/dL 29 133.3±25.9 13 123.8±25.8 58 145.8±33.1b 54 127.1±27.7b 48 137.7±37.4 33 131.8±24.8
    Lumbar spine BMD Z-score - - - - 54 −1.4 (−2.4 to −0.8) 6 −1.7 (−2.7 to −0.2) 31 −1.6 (−2.4 to −0.7) 8 −1.7 (−2.8 to −1.6)
    Femoral neck BMD Z-score - - - - 43 −1.0 (−1.8 to −0.3) 6 −1.6 (−2.1 to 0.2) 29 −0.9 (−1.2 to −0.1) 8 −0.9 (−1.7 to 0.2)
    Outcome variable Unadjusted, β (95% CI) Adjusted, β (95% CI)c
    Body mass index, kg/m2 0.12 (−0.11 to 0.35) −0.03 (−0.33 to 0.27)
    Body mass index Z-score 0.04 (−0.04 to 0.12) −0.01 (−0.10 to 0.08)
    IGF-1, μg/L −4.42 (−7.60 to −1.25)b −2.19 (−5.95 to 1.57)
    IGFBP-3, μg/L −71.21 (−114.18 to −28.23)b −52.00 (−105.16 to 1.16)
    Fasting glucose, mg/dL 0.53 (−0.06 to 1.12) 0.93 (0.16 to 1.70)a
    Glycated hemoglobin, % 0.01 (−0.02 to 0.04) 0.00 (−0.04 to 0.04)
    Total cholesterol, mg/dL 1.95 (0.35 to 3.55)a 1.44 (-0.69 to 3.57)
    Triglycerides, mg/dL 4.80 (−1.09 to 10.69) 4.13 (−3.84 to 12.09)
    HDL cholesterol, mg/dL −1.06 (−2.03 to −0.08)a −0.79 (−2.10 to 0.51)
    LDL cholesterol, mg/dL 3.46 (1.11 to 5.81)b 2.00 (−1.14 to 5.14)
    Non-HDL cholesterol, mg/dL 4.81 (2.46 to 7.16)b 3.26 (0.10 to 6.42)a
    Table 1. Etiology of Childhood-Onset Growth Hormone Deficiency

    Table 2. Changes in Clinical Characteristics at the End of GH Treatment, at the Time of Re-Evaluation, and 1 Year after Treatment Resumption in Patients with Complete Data at All Visits

    Values are expressed as mean±standard deviation, number (%), or median (interquartile range).

    GH, growth hormone; IGF-1, insulin-like growth factor-1; IGFBP-3, IGF-binding protein-3; HDL, high-density lipoprotein; LDL, low-density lipoprotein; BMD, bone mineral density.

    Table 3. Comparison of Clinical Characteristics by the Length of GH Treatment Interruption

    Values are expressed as mean±standard deviation or median (interquartile range).

    GH, growth hormone; IGF-1, insulin-like growth factor-1; IGFBP-3, IGF-binding protein-3; HDL, high-density lipoprotein; LDL, low-density lipoprotein; BMD, bone mineral density.

    P<0.05;

    P<0.01.

    Table 4. Associations of Clinical Characteristics with the Duration of GH Treatment Interruption (years) at Re-Evaluation

    GH, growth hormone; CI, confidence interval; IGF-1, insulin-like growth factor-1; IGFBP-3, IGF-binding protein-3; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

    P<0.05;

    P<0.01;

    Models were adjusted for age, sex, peak growth hormone levels at re-evaluation for body mass index and body mass index Z-scores; the models were adjusted for age, sex, body mass index Z-scores, and peak GH levels for other parameters.

    Table 1.

    Table 2.

    Table 3.

    Table 4.

    Endocrinol Metab : Endocrinology and Metabolism
    © Korean Endocrine Society.
    TOP